Esperion Therapeutics Earning Date (ESPR)

USA |NASDAQ |USD

ESPR Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Aug 1, 2022 Jun 2022 - - $-1.67
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Aug 1, 2022 Jun 2022 - - $40.66M

Esperion Therapeutics's next earnings date is Monday, Aug 1, 2022 for the fiscal quarter ending Jun 2022.

ESPR Earnings Date & History Chart

ESPR Earnings & Revenue Forecast

ESPR Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 11 $-5.23 $-9.00 $1.28

ESPR Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2022 7 / 2 $-5.58 $-5.04 $-5.34

ESPR Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 11 $119.74M $53.96M $414.50M

ESPR Earnings Date & Revenue History

ESPR Earnings History

|
Show More
Show More

ESPR Revenue History

|
Show More
Show More

Esperion Therapeutics Next Earnings Date & Report

ESPR Next Earnings Date & Report Preview: Jun 2022 (FQ)

ESPR's next earnings date is Monday, Aug 1, 2022 for the fiscal quarter ending Jun 30, 2022.

Esperion Therapeutics Previous Earnings Dates & Reports

ESPR Previous Earnings Date & Report Recap: Mar 2022 (FQ)

Esperion Therapeutics's previous earnings date was May 2, 2022 for its fiscal quarter ended Mar 31, 2022.

ESPR Previous Earnings Date & Report Recap: Dec 2021 (FY)

Esperion Therapeutics's previous annual earnings date was Feb 22, 2022 for its fiscal year ended Dec 31, 2021.

ESPR's earnings per share (EPS) was $-9.56, beating the consensus analysts forecast of $-10.29 by -7.09% , and lower than the previous year's EPS (Dec 2020) by 74.45%.

Revenues were $78.45M, better than the forecast of $77.74M by 0.91%, and down by -65.52% from previous year's revenue.

The company reported a net income of $-269.11M.

Esperion Therapeutics reported a free cash flow of $-263.81M for its fiscal year, compared to $-98.55M a year ago.

The company ended the fiscal year with $260.20M in total debt, an increase of 40.34% compared to the previous year.